This article is more than 5 years old. Information may no longer be current.

Clearside’s retinal vein occlusion therapy fails to meet phase 3 endpoint

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Xipere, an investigational treatment for retinal vein occlusion, did not achieve its phase 3 clinical trial primary endpoint, Clearside Biomedical announced in a press release.

The multicenter, multi-country, randomized, masked phase 3 SAPPHIRE trial compared Xipere — formerly called suprachoroidal CLS-TA, a proprietary suspension of triamcinolone acetonide — used together with intravitreal Eylea (aflibercept, Regeneron) to Eylea monotherapy.

A similar proportion of patients in both arms of the trial gained at least 15 ETDRS letters in best corrected visual acuity after 8 weeks, with no additional visual outcome benefit for those treated with the combination therapy, the release said.

“In light of these 8-week topline data, we plan to discontinue clinical development of combination therapy for RVO, which includes SAPPHIRE and its companion phase 3 clinical trial TOPAZ,” Daniel White, CEO and president of Clearside, said in the release.